[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Dore DD, Lapane KL, Trivedi AN, Mor V, Weinstock MA: Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. Ann Intern Med; 2009 Jan 6;150(1):9-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial.
  • BACKGROUND: Recent evidence suggests that statins may prevent cancer.
  • OBJECTIVE: To quantify the association between statin use and the occurrence of keratinocyte carcinoma in high-risk veterans.
  • PARTICIPANTS: 1037 participants of the Veterans Affairs Topical Tretinoin Chemoprevention Trial, a randomized, multicenter, double-blind, vehicle-controlled trial of topical tretinoin, 0.1%, for prevention of keratinocyte carcinoma conducted from November 1998 to November 2004.
  • MEASUREMENTS: Time to first occurrence of keratinocyte carcinoma on the face or ears.
  • In the propensity score-matched analysis, statin use at randomization was not associated with keratinocyte carcinoma (rate ratio, 0.92 [95% CI, 0.73 to 1.16]), a finding that was consistent with the estimates derived from the Cox proportional hazards regression (rate ratio, 0.84 [CI, 0.70 to 1.02]).
  • CONCLUSION: These data show no conclusive or consistent relationship between long-term statin use and risk for keratinocyte carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2006 Jun 21;295(23):2721; author reply 2721-2 [16788124.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):549-59 [16899775.001]
  • [Cites] Int J Clin Pract. 2006 Sep;60(9):1028-34 [16939542.001]
  • [Cites] Am J Cardiol. 2006 Oct 1;98(7):923-8 [16996875.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Circulation. 2007 Jan 2;115(1):27-33 [17179016.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 3;99(1):32-40 [17202111.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):213-9 [17235211.001]
  • [Cites] Dement Geriatr Cogn Disord. 2007;23(3):194-201 [17259710.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):279-84 [17482716.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):393-402 [17681160.001]
  • [Cites] J Invest Dermatol. 2007 Oct;127(10):2323-7 [17522705.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2218-25 [17971519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32 [18006910.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):134-9 [18182618.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):88-94 [18199714.001]
  • [Cites] Urology. 2008 Jan;71(1):118-22 [18242378.001]
  • [Cites] Am J Med. 2008 Apr;121(4):302-9 [18374689.001]
  • [Cites] Am J Gastroenterol. 2008 Apr;103(4):825-37 [18371146.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):767-74 [18322813.001]
  • [Cites] JAMA. 2000 Jun 28;283(24):3211-6 [10866868.001]
  • [Cites] Arch Intern Med. 2000 Aug 14-28;160(15):2363-8 [10927735.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]
  • [Cites] Med Care. 2003 Jun;41(6):761-74 [12773842.001]
  • [Cites] Pharmacotherapy. 2003 Jun;23(6):726-30 [12820814.001]
  • [Cites] Arch Intern Med. 2004 Jan 26;164(2):146-52 [14744837.001]
  • [Cites] Med Care Res Rev. 2003 Sep;60(3 Suppl):92S-123S [15095548.001]
  • [Cites] Am J Cardiol. 2004 May 1;93(9):1124-9 [15110204.001]
  • [Cites] Lancet. 2004 May 15;363(9421):1607-8 [15145635.001]
  • [Cites] Lancet Neurol. 2004 Jun;3(6):369-71 [15157852.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1079-85 [15381547.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Arch Dermatol. 1991 Aug;127(8):1194-7 [1863078.001]
  • [Cites] J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90 [8410092.001]
  • [Cites] Arch Dermatol. 1993 Oct;129(10):1286-90 [8215493.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):489-94 [7829262.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):164-9 [7857112.001]
  • [Cites] J R Soc Med. 1997 Jul;90(7):371-4 [9290417.001]
  • [Cites] JAMA. 1998 May 27;279(20):1615-22 [9613910.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):643-7 [15578694.001]
  • [Cites] N Engl J Med. 2005 Apr 7;352(14):1425-35 [15755765.001]
  • [Cites] N Engl J Med. 2005 May 26;352(21):2184-92 [15917383.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):465-76 [15651087.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(4):CD003697 [16235336.001]
  • [Cites] JAMA. 2005 Nov 16;294(19):2437-45 [16287954.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Dec;5(8):579-94 [16375664.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):74-80 [16391219.001]
  • [Cites] Oncologist. 2006 Mar;11(3):306-15 [16549815.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] Am J Epidemiol. 2006 Jun 15;163(12):1149-56 [16624967.001]
  • [Cites] JAMA. 2006 Jun 21;295(23):2720-1; author reply 2721-2 [16788122.001]
  • (PMID = 19124815.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00007631
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106592; United States / NCI NIH HHS / CA / R25CA087972; United States / NCI NIH HHS / CA / R01CA106807; United States / NIAMS NIH HHS / AR / R01 AR049342; United States / AHRQ HHS / HS / 5T32HS000011-21; United States / NCI NIH HHS / CA / R01 CA106807; United States / NCI NIH HHS / CA / R25 CA087972; United States / NCI NIH HHS / CA / R01CA106592; United States / AHRQ HHS / HS / T32 HS000011; United States / NIAMS NIH HHS / AR / R01AR49342
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  • [Other-IDs] NLM/ NIHMS507348; NLM/ PMC3771656
  •  go-up   go-down


2. Landström FJ, Nilsson CO, Crafoord S, Reizenstein JA, Adamsson GB, Löfgren LA: Electroporation therapy of skin cancer in the head and neck area. Dermatol Surg; 2010 Aug;36(8):1245-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electroporation therapy of skin cancer in the head and neck area.
  • BACKGROUND: Electroporation therapy is a new cancer treatment modality in which a locally applied electrical field enhances cell membrane permeability, allowing greater intracellular accumulation of a chemotherapeutic agent.
  • OBJECTIVE: To evaluate the efficacy of electroporation therapy in treating basal cell and squamous cell carcinomas of the skin.
  • MATERIALS AND METHODS: Six patients with skin cancer of the head and neck were treated using electroporation therapy with intratumorally injected bleomycin.
  • One additional recurrence was recorded 6 months after the follow-up period CONCLUSION: Electroporation therapy is a promising new cancer treatment that should be further evaluated as an alternative to surgery, especially in complicated skin cancer.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Electrochemotherapy. Head and Neck Neoplasms / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Ear Neoplasms / drug therapy. Female. Humans. Male. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2011 Feb;37(2):286; author reply 287 [21324036.001]
  • (PMID = 20666812.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


3. Biel M: Advances in photodynamic therapy for the treatment of head and neck cancers. Lasers Surg Med; 2006 Jun;38(5):349-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photodynamic therapy (PDT) is an FDA-approved minimally invasive medical treatment modality that utilizes light in the presence of oxygen to activate photosensitizing agents that are relatively selectively concentrated in abnormal or neoplastic cells resulting in cell death.
  • In the United States, US Food and Drug administration approval has been given for the use of PDT in the treatment of Barrett's esophagus, obstructing esophageal carcinoma and early and obstructing tracheobronchial carcinoma using the photosensitizer Photofrin; actinic keratosis using the photosensitizer Levulan (aminolevulinic acid); and macular degeneration using the photosensitizer BPD.
  • In the EU the above noted indications have also been approved in addition to the treatment of early head and neck cancers and palliative treatment of head and neck cancer using the photosensitizer Foscan; and treatment of basal and squamous cell skin cancers using the photosensitizer Metvix.
  • [MeSH-major] Dihematoporphyrin Ether / therapeutic use. Head and Neck Neoplasms / therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ambulatory Care. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. Male. Melanoma / therapy. Middle Aged. Minnesota / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Papilloma / therapy. Retrospective Studies. Sarcoma, Kaposi / therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788923.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


Advertisement
4. Geng A, Weinstock MA, Hall R, Eilers D, Naylor M, Kalivas J, VATTC Trial Group: Tolerability of high-dose topical tretinoin: the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Br J Dermatol; 2009 Oct;161(4):918-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Topical tretinoin is a medication commonly used for acne that has potential application in the long-term treatment of photodamaged skin.
  • METHODS: A randomized, multicentre, double-blind, controlled trial for chemoprevention of keratinocyte carcinomas (i.e. basal cell or squamous cell carcinomas) using topical tretinoin cream to the face and ears was conducted.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19681859.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106592; United States / NCI NIH HHS / CA / R25CA087972; United States / NCI NIH HHS / CA / R01CA106807; United States / NCI NIH HHS / CA / R01CA106592; United States / NIAMS NIH HHS / AR / R01AR49342
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  • [Investigator] Weinstock M; Marcolivio K; Weinstock M; Bingham S; DiGiovanna JJ; Hall R; Naylor M; Taylor JR; Vertrees J; White C; Hall R; Sidhu-Malik N; Hannah D; Eilers D; Liang T; Sakla N; Kreuger A; Cole G; Jeffes E; Labrador T; Taylor JR; Kirsner R; Kerri JE; Falabella AG; Givens M; Naylor M; Benson MB; Perry L; Kalivas J; Yanni C; Targovnik S; Austin J; Collier S; Collins JF; Bingham S; Calvert B; Connor P; Crigler C; Davis D; Grubb P; Kelly J; Kirk G; Lawson K; Linzy L; Palmer L; Rhoads M; Sather M; Copeland E; Fye C; Gagne W; de Naranjo PG; Messick C; Vertrees J; Piepkorn M; White C; Lew R; Braverman I; Cole B; Kalish R; McLean D; Thiers BH
  •  go-up   go-down


5. Zhu XG, Park KS, Kaneshige M, Bhat MK, Zhu Q, Mariash CN, McPhie P, Cheng SY: The orphan nuclear receptor Ear-2 is a negative coregulator for thyroid hormone nuclear receptor function. Mol Cell Biol; 2000 Apr;20(7):2604-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The orphan nuclear receptor Ear-2 is a negative coregulator for thyroid hormone nuclear receptor function.
  • Recently, we found that TR-mediated transcriptional responses varied in six cell lines derived from different tissues.
  • We therefore used human TR subtype beta1 (TRbeta1) as bait to search for coregulators in human colon carcinoma RKO cells with a yeast two-hybrid system.
  • One of the three positive clones was identified as Ear-2, which is a distant member of the chick ovalbumin upstream promoter-transcription factors of the orphan nuclear receptor family.
  • The physical interaction between Ear-2 and TRbeta1 was further confirmed by specific binding of Ear-2 to glutathione S-transferase-TRbeta1.
  • In addition, Ear-2 was found to associate with TRbeta1 in cells.
  • Using reporter systems, we found that both the basal activation and the T3-dependent activation mediated by TRbeta1 were repressed by Ear-2 in CV1 cells.
  • In RKO cells, however, the T3-independent transcriptional activity was more sensitive to the repression effect of Ear-2 than the T3-dependent transcriptional activity.
  • The repression effect of Ear-2 was reversed by steroid hormone receptor coactivator 1.
  • These findings further strengthen the hypothesis that the diverse activities of TR are achieved via a large network of coregulators that includes Ear-2.

  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - V-erbA-related gene / NR2F6 - data and references .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1995 Dec 14;378(6558):690-7 [7501015.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1354-7 [7481822.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4273-7 [8633054.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8329-33 [8710870.001]
  • [Cites] Endocrinology. 1996 Oct;137(10):4073-81 [8828459.001]
  • [Cites] Cell. 1996 Nov 29;87(5):953-9 [8945521.001]
  • [Cites] Nature. 1996 Dec 19-26;384(6610):641-3 [8967953.001]
  • [Cites] J Biol Chem. 1997 Feb 14;272(7):4129-34 [9020124.001]
  • [Cites] Mol Cell Endocrinol. 1997 Jan 3;126(1):75-81 [9027365.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9048-54 [9083030.001]
  • [Cites] Endocr Rev. 1997 Apr;18(2):229-40 [9101138.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):194-8 [9296499.001]
  • [Cites] J Mol Endocrinol. 1997 Oct;19(2):163-72 [9343308.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):669-74 [9435250.001]
  • [Cites] Science. 1998 Mar 20;279(5358):1922-5 [9506940.001]
  • [Cites] Endocrinology. 1998 May;139(5):2493-500 [9564863.001]
  • [Cites] Mol Cell Endocrinol. 1998 Feb;137(2):145-54 [9605516.001]
  • [Cites] Science. 1998 Jun 12;280(5370):1747-9 [9624051.001]
  • [Cites] Nature. 1998 Sep 10;395(6698):137-43 [9744270.001]
  • [Cites] Recent Prog Horm Res. 1998;53:351-92; discussion 392-4 [9769715.001]
  • [Cites] Genes Dev. 1998 Nov 1;12(21):3357-68 [9808623.001]
  • [Cites] Cell. 1999 Apr 2;97(1):17-27 [10199399.001]
  • [Cites] Endocr Rev. 1999 Jun;20(3):321-44 [10368774.001]
  • [Cites] Nucleic Acids Res. 1988 Dec 9;16(23):11057-74 [2905047.001]
  • [Cites] Endocrinology. 1991 May;128(5):2601-9 [1708338.001]
  • [Cites] Mol Endocrinol. 1991 Apr;5(4):485-92 [1922081.001]
  • [Cites] Nature. 1992 Mar 12;356(6365):152-4 [1545867.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Mar 16;183(2):492-8 [1550558.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7737-41 [1502193.001]
  • [Cites] J Clin Invest. 1993 Oct;92(4):1986-93 [8408652.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):7927-31 [8058736.001]
  • [Cites] J Immunol Methods. 1994 Dec 2;176(2):145-52 [7983375.001]
  • [Cites] Nature. 1995 Oct 5;377(6548):397-404 [7566114.001]
  • [Cites] Nucleic Acids Res. 1995 Oct 25;23(20):4143-50 [7479078.001]
  • [Cites] Cell. 1996 May 3;85(3):403-14 [8616895.001]
  • (PMID = 10713182.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK050456; United States / NIDDK NIH HHS / DK / P30 DK50456
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NR2F6 protein, human; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Steroid; 0 / Receptors, Thyroid Hormone; 0 / Repressor Proteins; 0 / Transcription Factors; 06LU7C9H1V / Triiodothyronine
  • [Other-IDs] NLM/ PMC85476
  •  go-up   go-down






Advertisement